Bradway Robert A 4

What Happened

• Robert A. Bradway, Amgen's Chairman, CEO and President, reported a tax-withholding/settlement transaction on shares: 21,294 shares were disposed (withheld) at a per-share value of $366.21, for a total value of $7,798,076. This was a share-for-tax payment (code F), not an open-market sale.

Key Details

• Transaction date: 2026-03-16; Form 4 filed: 2026-03-18 (timely filing).
• Price per share: $366.21; total value of withheld shares: $7,798,076.
• Shares withheld included 2,696 Dividend Equivalents (DEs) credited to unvested RSUs under Amgen’s 2009 Equity Incentive Plan (see footnote): DEs are paid out in shares one-for-one per the vesting schedule, with cash for any fractional share.
• Nature of transaction: F = payment of exercise price or tax liability (share withholding to cover taxes), not a market sale.
• Shares owned after transaction: not specified in this summary—see the Form 4 for reported beneficial ownership totals.

Context

• This is a routine tax-withholding event tied to equity compensation (RSUs/DEs). It reflects tax settlement rather than a decision to sell shares on the open market, so it should not be interpreted as a directional buy/sell signal by itself.